|Bid||7.50 x 100|
|Ask||13.61 x 200|
|Day's Range||13.25 - 13.56|
|52 Week Range||10.29 - 14.87|
|PE Ratio (TTM)||15.73|
|Earnings Date||Feb 7, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||12.40|
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease .
LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK ) ("GSK"), following ...
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna ...
Innoviva, Inc. today announced that management will present at the following healthcare-focused investment banking conferences in November 2017:
Innoviva, Inc. today reported financial results for the third quarter of 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® from Glaxo Group Limited during the third quarter of 2017 were $51.9 million, up 42% from $36.5 million in the third quarter of 2016.
Work NEW YORK, NY / ACCESSWIRE / October 25, 2017 / Innoviva, Inc. (NASDAQ: INVA ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 25, 2017 at 5:00 PM Eastern ...
Innoviva, Inc. announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017.